Merck, known as MSD outside of the United States and Canada, announced topline results from LITESPARK-005, the first positive Phase 3 trial investigating WELIREG, Merck’s oral hypoxia-inducible factor-2 alpha inhibitor.
Merck, known as MSD outside of the United States and Canada, announced topline results from LITESPARK-005, the first positive Phase 3 trial investigating WELIREG, Merck’s oral hypoxia-inducible factor-2 alpha inhibitor.